^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Taxanes combined with Apatinib mesylate in the treatment for patients with advanced breast cancer: an open-label, single-arm, single-center clinical research
Excerpt:
...HER2 positive patients allowed by bead an auxiliary or first-line treatment history; 5. ...
Trial ID:
Source:
Title:
Clinical curative effect of neoadjuvant chemotherapy combined with immunotherapy and its impact on immunological function and the expression of ER, PR, HER-2 & SATB1 in HER-2-Positive breast cancer patients
Published date:
01/25/2022
Excerpt:
The subjects of study were 80 patients with HER-2-positive breast cancer....Patients in the control group were provided with neoadjuvant chemotherapy using TAC regimen merely; while those in the study group received oral administration of Apatinib Mesylate (500mg/d; three weeks a cycle) on the basis of the TAC regimen....The total response rate was 77.5% and 55% in the study group and the control group, respectively, with an obviously better outcome in the former group than that in the latter group (p=0.03)....Neoadjuvant chemotherapy combined with immunotherapy has significant effect on the treatment of HER-2-positive breast cancer patients.
Secondary therapy:
TAC
DOI:
10.12669/pjms.38.3.5199
